Risk of endometrial cancer after RRSO in BRCA 1/2 carriers: a multicentre cohort study

Pla-Juher, Helena
Pardo, Marta
Izquierdo, Àngel J.
Darder, Esther
Carbó Bagué, Anna
Munté, Elisabet
Torres-Esquius, Sara
Balmaña Gelpi, Judith
Lázaro, Concepción
Brunet, Joan M.
Compartir
To know the risk of endometrial cancer (EC) in a population of women with BRCA 1/2 pathogenic or likely pathogenic variants after risk-reducing salpingo-oophorectomy (RRSO). Methods: The study cohort included data from 857 women with BRCA mutations who underwent RRSO visited four hospitals in Catalonia, Spain, from January 1, 1999 to April 30, 2019. Standardized incidence ratio (SIR) of EC was calculated in these patients using data from a regional population-based cancer registry. Results: After RRSO, eight cases of EC were identified. Four in BRCA 1 carriers and four in BRCA2 carriers. The expected number of cases of EC was 3.67 cases, with a SIR of 2.18 and a 95% CI (0.93–3.95). Conclusions: In our cohort, the risk of EC in BRCA1/2 carriers after RRSO is not greater than expected. Hysterectomy is not routinely recommended for these patients ​
Aquest document està subjecte a una llicència Creative Commons:Reconeixement (by) Creative Commons by4.0